介入治疗肝硬化门静脉高压症研究进展与挑战*

doi:10.3969/j.issn.1672-5069.2024.05.003

Abstract

Zhang Zhiqiang, Fang Jian, Li Dongliang. Strategy and challenges of interventional treatment in patients with liver cirrhosis and portal hypertension[J]. Journal of Practical Hepatology, 2024, 27(5): 650-653.

References

[1] Moller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int. 2018;38(4):570-580.
[2] Rosch J, Hanafee WN, Snow H. Transjugular portal venography and radiologic portacaval shunt: an experimental study. Radiology,1969,92(5):1112-1114.
[3] Palmaz JC, Sibbitt RR, Tio FO, et al. Expandable intraluminal vascular graft: a feasibility study. Surgery, 1986,99(2):199-205.
[4] Richter GM, Noldge G, Roeren T, et al. Historical and conceptional aspects of TIPSS. Radiologe, 1994,34(4):158-163.
[5] Bettinger D, Thimme R, Schultheiss M. Implantation of transjugular intrahepatic portosystemic shunt (TIPS): indication and patient selection. Curr Opin Gastroenterol, 20223,8(3):221-229.
[6] Zheng M, Chen Y, Bai J, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients: meta-analysis update. J Clin Gastroenterol, 2008,42(5):507-516.
[7] Boyer TD, Haskal ZJ, American Association for the Study of Liver D. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology,2010,51(1):306.
[8] Salerno F, Camma C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology, 2007,133(3):825-834.
[9] Bucsics T, Hoffman S, Grunberger J, et al. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. Liver Int,2018,38(6):1036-1044.
[10] Grunwald D, Tapper EB, Jiang ZG, et al. A standardized assessment of functional disability predicts 1-year mortality in patients undergoing transjugular intrahepatic portosystemic shunt for refractory ascites. J Clin Gastroenterol, 2016,50(1):75-79.
[11] Mancuso A. An update on management of Budd-Chiari syndrome. Ann Hepatol, 2014,13(3):323-326.
[12] Raja K, Jacob M, Asthana S. Portal vein thrombosis in cirrhosis. J Clin Exp Hepatol, 2014,4(4):320-331.
[13] European Association for the Study of the Liver. Electronic address eee. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol, 2016,64(1):179-202.
[14] Habib A, Desai K, Hickey R, et al. Portal vein recanalization-transjugularintrahepatic portosystemic shunt using the transsplenic approach to achieve transplant candidacy in patients with chronic portal vein thrombosis. J Vasc Interv Radiol, 2015,26(4):499-506.
[15] 李莹, 练晶晶, 罗添成, 等. 预防肝硬化食管静脉曲张再出血的成本效果研究. 中华消化杂志, 2016,36(2): 113-118.
[16] Khalili H, Goldman D, Frischhertz S, et al. Clinical images: transjugular intrahepatic portosystemic shunt reduction for management of recurrent hepatic encephalopathy. Ochsner J, 2017, 17(4): 311-316.
[17] Hausegger KA, Karnel F, Georgieva B, et al. Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft. J Vasc Interv Radiol, 2004,15(3):239-248.
[18] Sauerbruch T, Mengel M, Dollinger M, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology, 2015,149(3):660-668, e661.
[19] Olson E, Yune HY, Klatte EC. Transrenal-vein reflux ethanol sclerosis of gastroesophageal varices. AJR,1984,143(3):627-628.
[20] Kanagawa H, Mima S, Kouyama H, et al. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol, 1996,11(1):51-58.
[21] Saad WE, Darcy MD. Transjugular intrahepatic portosystemic shunt (TIPS) versus balloon-occluded retrograde transvenous obliteration (BRTO) for the management of gastric varices. Semin Intervent Radiol, 2011,28(3):339-349.
[22] Saad WE. Balloon-occluded retrograde transvenous obliteration of gastric varices: concept, basic techniques, and outcomes. Semin Intervent Radiol, 2012,29(2):118-128.
[23] Takuma Y, Nouso K, Makino Y, et al. Prophylactic balloon-occluded retrograde transvenous obliteration for gastric varices in compensated cirrhosis. Clin Gastroenterol Hepatol, 2005,3(12):1245-1252.
[24] Park JK, Saab S, Kee ST, et al. Balloon-occluded retrograde transvenous obliteration (BRTO) for treatment of gastric varices: Review and Meta-analysis. Dig Dis Sci,2015,60(6):1543-1553.
[25] Saad WE, Sabri SS. Balloon-occluded retrograde transvenous obliteration (BRTO): Technical results and outcomes. Semin Intervent Radiol, 2011,28(3):333-338.
[26] FE M. Embolic therapy of hypersplenism. Invest Radiol, 1973,8:280-281.
[27] Spigos DG, Jonasson O, Mozes M, et al. Partial splenic embolization in the treatment of hypersplenism. AJR , 1979,132(5):777-782.
[28] Bisharat N, Omari H, Lavi I, et al. Risk of infection and death among post-splenectomy patients. J Infect,2001,43(3):182-186.
[29] Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg, 1991,78(9):1031-1038.
[30] Ahuja C, Farsad K, Chadha M. An overview of splenic embolization. AJR, 2015,205(4):720-725.
[31] Sangro B, Bilbao I, Herrero I, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology, 1993,18(2):309-314.
[32] Bessoud B, Denys A, Calmes JM, et al. Nonoperative management of traumatic splenic injuries: is there a role for proximal splenic artery embolization? AJR , 2006,186(3):779-785.
[33] Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature. J Vasc Interv Radiol, 2007,18(4):463-481.
[34] Moon E, Tam MD, Kikano RN, et al. Prophylactic antibiotic guidelines in modern interventional radiology practice. Semin Intervent Radiol, 2010,27(4):327-337.
[35] 杨卷红,吴博云,李金保,等.急诊PTVE治疗肝硬化并发食管胃底静脉曲张破裂出血.实用肝脏病杂志.2013;16(6): 548-549.

Strategy and challenges of interventional treatment in patients with liver cirrhosis and portal hypertension

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wei Xinhuan, Liu Yali, Zhang Jing, et al. Current landscape and future perspectives of metabolic-associated fatty liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(5): 641-645.
[2]	Xin Liangliang, Wen Zhi. Assessment of esophageal varices by 2D-SWE technology, FIB-4 and serum VEGF level in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(5): 737-740.
[3]	Ruini, Wang Shasha, Jia Zebo, et al. Endoscopic variceal ligation with lauromacrogol and snake venom hemocoagulase injection in treating patients with hepatitis B liver cirrhosis complicated by esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2024, 27(5): 741-744.
[4]	Tian Lin, Kang Ying, Cui Jie, et al. Esophageal variceal ligation with auxiliary oral thrombin and intravenous octreotide administration in the treatment of cirrhotics with esophageal and gastric variceal bleeding [J]. Journal of Practical Hepatology, 2024, 27(5): 745-748.
[5]	Li Shuangling, Liu Li, Chen Yi, et al. Intestinal barrier function index changes in patients with compensated hepatitis B cirrhosis and high serum viral loads undergoing tenofovir alafenamide fumarate or entecavir therapy [J]. Journal of Practical Hepatology, 2024, 27(5): 749-752.
[6]	Lian Zuoqin, Wang Shiming, Zhang Jia, et al. Anti-fibrotic efficacy of tenofovir disoproxil fumarate and Compound Fufang Biejia Ruangan tablet in the treatment of patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(5): 753-756.
[7]	Zan Shuangjiang, Yu Tian, Dai Jing. Direct-acting antiviral agent treatment ameliorate thrombocytopenia in patients with hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(5): 757-760.
[8]	Zhang Huaidong, Lei Yu, Zhou Zhi. Clinical feature of extra-liver abscess in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(5): 761-764.
[9]	Ren Hao, Xiong Qingfang. Diagnostic performance of fournoninvasive detection indexes in predicting liver cirrhosis in patients with autoimmune liver diseases [J]. Journal of Practical Hepatology, 2024, 27(4): 535-538.
[10]	Xing Shilei, Li Zhihui, Ning Xiujing. Changes of serum MCP-1, TNF-α and IL-10 levels in patients with hepatitis B cirrhosis and spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2024, 27(4): 563-566.
[11]	Aizijiang·Aimaiti, Abdusikul·Abdulmijiti, Dilinur· Abdulrahiman, et al. Clinical observation of bone marrow mesenchymal stem cell transplantation and herbal medicine in treatment of patients with decompensated cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(4): 567-570.
[12]	Fan Yanan, Ji Tongtong, Li Xinfei, et al. Common causes and complications of patients with liver cirrhosis in two medical centers [J]. Journal of Practical Hepatology, 2024, 27(4): 571-574.
[13]	Li Weixin, Suo Aijun, Wang Xiufeng. Dezocine anesthesia induction and propofol target-controlled infusion maintaining in patients withliver cirrhosis and esophageal variceal bleeding underwent endoscopic sclerotherapy [J]. Journal of Practical Hepatology, 2024, 27(4): 575-578.
[14]	Tang Zeyu, Gu Fei, Zhou Jianwen, et al. Diagnostic efficacy of CT parameters and FIB-4 and serum VEGF levels in predicting esophageal varices in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(4): 579-582.
[15]	Bao Yingjun, Zhang Yuan, Gu Junpeng, et al. Combined stents versus Viatorr stents in transjugular intrahepatic portosystemic stent shunt for treatment of patients with liver cirrhosis and complicated portal hypertension [J]. Journal of Practical Hepatology, 2024, 27(4): 583-586.